Neuvivo
PrivateLast Round
VC Round
Jun 15, 2023
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neuvivo is a biopharmaceutical company that develops novel therapeutics for the treatment of Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuvivo Comparables
Compare Neuvivo with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunity Pharma Ltd. | 82% | |
| AL-S Pharma AG | 81% | |
| Brainstorm Cell Therapeutics Inc. | 81% | |
Neuvivo Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jun 15, 2023 | ||||
| Seed | May 26, 2022 |
Neuvivo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| PrimeStreet Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 19, 2026
Monthly visitors increased 52% MoM.
- Apr 19, 2026
Monthly visitors grew 79% MoM.
Neuvivo Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |